120 related articles for article (PubMed ID: 32034707)
21. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
[TBL] [Abstract][Full Text] [Related]
22. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.
Dhandapani KM; Mahesh VB; Brann DW
J Neurochem; 2007 Jul; 102(2):522-38. PubMed ID: 17596214
[TBL] [Abstract][Full Text] [Related]
23. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
24. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
[TBL] [Abstract][Full Text] [Related]
25. Targeting the erythropoietin receptor on glioma cells reduces tumour growth.
Pérès EA; Valable S; Guillamo JS; Marteau L; Bernaudin JF; Roussel S; Lechapt-Zalcman E; Bernaudin M; Petit E
Exp Cell Res; 2011 Oct; 317(16):2321-32. PubMed ID: 21749867
[TBL] [Abstract][Full Text] [Related]
26. Is mda-7/IL-24 a potential target and biomarker for enhancing drug sensitivity in human glioma U87 cell line?
Wang Q; Zhu Y; Yang P
Anat Rec (Hoboken); 2013 Aug; 296(8):1154-60. PubMed ID: 23794295
[TBL] [Abstract][Full Text] [Related]
27. Roles of purinergic P2X
McLarnon JG
Cancer Lett; 2017 Aug; 402():93-99. PubMed ID: 28536012
[TBL] [Abstract][Full Text] [Related]
28. Targeting malignant glioma survival signalling to improve clinical outcomes.
Wong ML; Kaye AH; Hovens CM
J Clin Neurosci; 2007 Apr; 14(4):301-8. PubMed ID: 17276069
[TBL] [Abstract][Full Text] [Related]
29. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma.
Mora R; Dokic I; Kees T; Hüber CM; Keitel D; Geibig R; Brügge B; Zentgraf H; Brady NR; Régnier-Vigouroux A
Glia; 2010 Aug; 58(11):1364-83. PubMed ID: 20607862
[TBL] [Abstract][Full Text] [Related]
30. Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.
Senger DL; Tudan C; Guiot MC; Mazzoni IE; Molenkamp G; LeBlanc R; Antel J; Olivier A; Snipes GJ; Kaplan DR
Cancer Res; 2002 Apr; 62(7):2131-40. PubMed ID: 11929835
[TBL] [Abstract][Full Text] [Related]
31. Guanosine promotes cytotoxicity via adenosine receptors and induces apoptosis in temozolomide-treated A172 glioma cells.
Oliveira KA; Dal-Cim TA; Lopes FG; Nedel CB; Tasca CI
Purinergic Signal; 2017 Sep; 13(3):305-318. PubMed ID: 28536931
[TBL] [Abstract][Full Text] [Related]
32. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2'-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells.
Ceruti S; Beltrami E; Matarrese P; Mazzola A; Cattabeni F; Malorni W; Abbracchio MP
Mol Pharmacol; 2003 Jun; 63(6):1437-47. PubMed ID: 12761355
[TBL] [Abstract][Full Text] [Related]
33. Purinergic signaling in glioma progression.
Braganhol E; Wink MR; Lenz G; Battastini AM
Adv Exp Med Biol; 2013; 986():81-102. PubMed ID: 22879065
[TBL] [Abstract][Full Text] [Related]
34. Glioma progression in diabesity.
Alarcón S; Niechi I; Toledo F; Sobrevia L; Quezada C
Mol Aspects Med; 2019 Apr; 66():62-70. PubMed ID: 30822432
[TBL] [Abstract][Full Text] [Related]
35. Survival and invasiveness of astrocytomas promoted by erythropoietin.
Mohyeldin A; Dalgard CL; Lu H; Mcfate T; Tait AS; Patel VC; Wong K; Rushing E; Roy S; Acs G; Verma A
J Neurosurg; 2007 Feb; 106(2):338-50. PubMed ID: 17410721
[TBL] [Abstract][Full Text] [Related]
36. Type-3 metabotropic glutamate receptors negatively modulate bone morphogenetic protein receptor signaling and support the tumourigenic potential of glioma-initiating cells.
Ciceroni C; Arcella A; Mosillo P; Battaglia G; Mastrantoni E; Oliva MA; Carpinelli G; Santoro F; Sale P; Ricci-Vitiani L; De Maria R; Pallini R; Giangaspero F; Nicoletti F; Melchiorri D
Neuropharmacology; 2008 Sep; 55(4):568-76. PubMed ID: 18621067
[TBL] [Abstract][Full Text] [Related]
37. 8-Cl-cAMP affects glioma cell-cycle kinetics and selectively induces apoptosis.
Grbovic O; Jovic V; Ruzdijic S; Pejanovic V; Rakic L; Kanazir S
Cancer Invest; 2002; 20(7-8):972-82. PubMed ID: 12449730
[TBL] [Abstract][Full Text] [Related]
38. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
39. Migration-prone glioma cells show curcumin resistance associated with enhanced expression of miR-21 and invasion/anti-apoptosis-related proteins.
Yeh WL; Lin HY; Huang CY; Huang BR; Lin C; Lu DY; Wei KC
Oncotarget; 2015 Nov; 6(35):37770-81. PubMed ID: 26473373
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo.
Milanovic D; Sticht C; Röhrich M; Maier P; Grosu AL; Herskind C
Oncotarget; 2015 Oct; 6(30):28938-48. PubMed ID: 26362268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
